On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo

Journal of Neurochemistry

Volumn 109, Issue 2, 2009, Pages 316-325

  Amori, Laura ^b   Guidetti, Paolo ^b   Pellicciari, Roberto ^c   Kajii, Yasushi ^d   Schwarcz, Robert ^a,b  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PERUGIA   (Italy)

^d MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

3 hydroxykynurenine; Excitotoxicity; Kynurenic acid; Quinolinic acid

Indexed keywords

3 HYDROXYKYNURENINE; [9 (4 AMINOPIPERAZIN 1 YL) 8 FLUORO 3 METHYL 6 OXO 2,3,5,6 TETRAHYDRO 4H OXA 3A AZA PHENALENE 5 CARBOXYLIC ACID; CARBOXYLIC ACID DERIVATIVE; ENZYME INHIBITOR; KYNURENIC ACID; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; KYNURENINE AMINOTRANSFERASE; KYNURENINE AMINOTRANSFERASE II; QUINOLINIC ACID; TRITIUM; U[2 (3,4 DICHLOROBENZOYL) CYCLOPROPANE 1 CARBOXYLIC ACID]; UNCLASSIFIED DRUG;

AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL COMPARTMENTALIZATION; COGNITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SYNTHESIS; IN VIVO STUDY; MALE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ANIMALS; BRAIN; ENZYME INHIBITORS; KYNURENINE; KYNURENINE 3-MONOOXYGENASE; MALE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRANSAMINASES;

MAMMALIA; RATTUS;

EID: 62649121884     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.05893.x     Document Type: Article

References (61)

1. Alkondon M., Pereira E. F., Yu P. et al. (2004) Targeted deletion of the kynurenine aminotransferase II gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus. J. Neurosci. 24, 4635 4648.
2. Amori L. (2003) Disegno e Sintesi di Nuovi Potenziali Inibitori Della Chinurenina 3-Idrossilasi, Enzima Della via Metabolica Delle Chinurenine. PhD Dissertation, University of Perugia, Perugia.
3. Belladonna M. L., Puccetti P., Orabona C., Fallarino F., Vacca C., Volpi C., Gizzi S., Pallotta M. T., Fioretti M. C. Grohmann U. (2007) Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes. Transplantation 84, S17 S20.
4. Bender D. A. McCreanor G. M. (1982) The preferred route of kynurenine metabolism in the rat. Biochim. Biophys. Acta 717, 56 60.
5. Bergeron R., Wu H.-Q., Potter M. C., Guidetti P. Schwarcz R. (2007) Mice with reduced brain kynurenic acid levels have high extracellular glutamate and show enhanced LTP in the hippocampus. Soc. Neurosci. Abstr. 32, 807 815.
6. Björklund H., Olson L., Dahl D. Schwarcz R. (1986) Short-and long-term consequences of intracranial injections of the excitotoxin quinolinic acid as evidenced by GFA immunohistochemistry of astrocytes. Brain Res. 371, 267 277.
7. Calka J., Wolf G. Schmidt W. (1996) Induction of cytosolic NADPH-diaphorase/nitric oxide synthase in reactive microglia/macrophages after quinolinic acid lesions in the rat striatum: an electron and light microscopical study. Histochem. Cell Biol. 105, 81 89.
8. Carpenedo R., Chiarugi A., Russi P., Lombardi G., Carlà V., Pellicciari R., Mattoli L. Moroni F. (1994) Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities. Neuroscience 61, 237 243.
9. 3H]-kynurenine in the developing rat brain in vivo: effect of intrastriatal ibotenate injections. Dev. Brain Res. 100, 73 81.
10. Ceresoli-Borroni G., Guidetti P. Schwarcz R. (1999) Acute and chronic changes in kynurenate formation following an intrastriatal quinolinate injection in rats. J. Neural Transm. 106, 229 242.
11. Ceresoli-Borroni G., Guidetti P., Amori L., Pellicciari R. Schwarcz R. (2007) Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications. J. Neurosci. Res. 85, 845 854.
12. Chess A. C. Bucci D. J. (2006) Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav. Brain Res. 170, 326 332.
13. Chess A. C., Simoni M. K., Alling T. E. Bucci D. J. (2007) Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr. Bull. 33, 797 804.
14. Chiarugi A., Cozzi A., Ballerini C., Massacesi L. Moroni F. (2001a) Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis. Neuroscience 102, 687 695.
15. Chiarugi A., Meli E. Moroni F. (2001b) Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid. J. Neurochem. 77, 1310 1318.
16. Christen S., Peterhans E. Stocker R. (1990) Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases. Proc. Natl Acad. Sci. USA 87, 2506 2510.
17. Clark C. J., Mackay G. M., Smythe G. A., Bustamante S., Stone T. W. Phillips R. S. (2005) Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition. Infect. Immun. 73, 5249 5251.
18. Dantzer R., O'Connor J. C., Freund G. G., Johnson R. W. Kelley K. W. (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46 56.
19. Erhardt S., Schwieler L., Nilsson L., Linderholm K. Engberg G. (2007) The kynurenic acid hypothesis of schizophrenia. Physiol. Behav. 92, 203 209.
20. Fukui S., Schwarcz R., Rapoport S. I., Takada Y Smith Q. R. (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 56, 2007 2017.
21. Gàl E. M. Sherman A. D. (1980) L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem. Res. 5, 223 239.
22. Giorgini F., Guidetti P., Nguyen Q., Bennett S. C. Muchowski P. J. (2005) A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat. Genet. 37, 526 531.
23. Giorgini F., Möller T., Kwan W. et al. (2008) Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J. Biol. Chem. 283, 7390 7400.
24. Grégoire L., Rassoulpour A., Guidetti P., Samadi P., Bédard P. J., Izzo E., Schwarcz R. Di Paolo T. (2008) Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav. Brain Res. 186, 161 167.
25. Guidetti P. Schwarcz R. (1999) 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur. J. Neurosci. 11, 3857 3863.
26. 3H]kynurenine in the rat +brain in vivo: evidence for the existence of a functional kynurenine pathway. J. Neurochem. 65, 2621 2632.
27. Guidetti P., Okuno E. Schwarcz R. (1997) Characterization of rat brain kynurenine aminotransferases I and II. J. Neurosci. Res. 50, 457 465.
28. Guidetti P., Amori L., Sapko M. T., Okuno E. Schwarcz R. (2007a) Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J. Neurochem. 102, 103 111.
29. Guidetti P., Hoffman G. E., Melendez-Ferro M., Albuquerque E. X. Schwarcz R. (2007b) Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia 55, 78 92.
30. Guillemin G. J., Kerr S. J., Smythe G. A., Armati P. J. Brew B. J. (1999) Kynurenine pathway metabolism in human astrocytes. Adv. Exp. Med. Biol. 467, 125 131.
31. Guillemin G. J., Kerr S. J., Smythe G. A., Smith D. G., Kapoor V., Armati P. J., Croitoru J. Brew B. J. (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 78, 842 853.
32. Guillemin G. J., Cullen K. M., Lim C. K., Smythe G. A., Garner B., Kapoor V., Takikawa O. Brew B. J. (2007) Characterization of the kynurenine pathway in human neurons. J. Neurosci. 27, 12884 12892.
33. Han Q., Cai T., Tagle D. A., Robinson H. Li J. (2008) Substrate specificity and structure of human aminoadipate aminotransferase/kynurenine aminotransferase II. Biosci. Rep. 28, 205 215.
34. Heyes M. P. Quearry B. J. (1988) Quantification of 3-hydroxykynurenine in brain by high-performance liquid chromatography and electrochemical detection. J. Chromatogr. 428, 340 344.
35. Heyes M. P., Achim C. L., Wiley C. A., Major E. O., Saito K. Markey S. P. (1996) Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 320, 595 597.
36. Kaper T., Looger L. L., Takanaga H., Platten M., Steinman L. Frommer W. B. (2007) Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. PLoS Biol. 5, e257.
37. Kerr S. J., Armati P. J., Pemberton L. A., Smythe G., Tattam B. Brew B. J. (1997) Kynurenine pathway inhibition reduces neurotoxicity of HIV-1-infected macrophages. Neurology 49, 1671 1681.
38. Lapin I. P. (1981) Kynurenines and seizures. Epilepsia 22, 257 265.
39. Miranda A. F., Boegman R. J., Beninger R. J. Jhamandas K. (1997) Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience 78, 967 975.
40. Moroni F. (1999) Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur. J. Pharmacol. 375, 87 100.
41. Moroni F., Cozzi A., Peruginelli F., Carpenedo R. Pellegrini-Giampietro D. E. (1999) Neuroprotective effects of kynurenine-3-hydroxylase inhibitors in models of brain ischemia. Adv. Exp. Med. Biol. 467, 199 206.
42. Müller N. Schwarz M. J. (2007) The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 12, 988 1000.
43. Németh H., Toldi J. Vécsei L. (2006) Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J. Neural Transm. Suppl. 70, 285 304.
44. Okuno E., Schmidt W., Parks D. A., Nakamura M. Schwarcz R. (1991) Measurement of rat brain kynurenine aminotransferase at physiological kynurenine concentrations. J. Neurochem. 57, 533 540.
45. Oxenkrug G. F. (2007) Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging. Ann. NY Acad. Sci. 1122, 35 49.
46. Pellicciari R., Amori L., Costantino G., Giordani A., Macchiarulo A., Mattoli L., Pevarello P., Speciale C. Varasi M. (2003) Modulation of the kynurenine pathway of tryptophan metabolism in search for neuroprotective agents. Focus on kynurenine-3-hydroxylase. Adv. Exp. Med. Biol. 527, 621 628.
47. Pellicciari R., Rizzo R., Costantino G., Marinozzi M., Amori L., Guidetti P., Wu H.-Q. Schwarcz R. (2006) Modulators of the kynurenine pathway of tryptophan metabolism. Synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor. ChemMedChem 1, 528 531.
48. Potter M. C., Elmer G. I., Guidetti P., Calu D. J. Schwarcz R. (2006) Improved behavioral performance of kynurenine aminotransferase II-deficient mice in hippocampus-based learning and memory paradigms. Soc. Neurosci. Abstr. 32, 265 269.
49. Reinhard J. F. Jr (2004) Pharmacological manipulation of brain kynurenine metabolism. Ann. NY Acad. Sci. 1035, 335 349.
50. Richter A. Hamann M. (2003) The kynurenine 3-hydroxylase inhibitor Ro 61-8048 improves dystonia in a genetic model of paroxysmal dyskinesia. Eur. J. Pharmacol. 478, 47 52.
51. Saito K., Nowak T. S. Jr., Markey S. P. Heyes M. P. (1993a) Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia. J. Neurochem. 60, 180 192.
52. Saito K., Quearry B. J., Saito M., Nowak T. S. Jr., Markey S. P. Heyes M. P. (1993b) Kynurenine 3-hydroxylase in brain: species activity differences and effect of gerbil cerebral ischemia. Arch. Biochem. Biophys. 307, 104 109.
53. Schroecksnadel K., Sarcletti M., Winkler C., Mumelter B., Weiss G., Fuchs D., Kemmler G. Zangerle R. (2008) Quality of life and immune activation in patients with HIV-infection. Brain Behav. Immun. 22, 881 889.
54. Schwarcz R. Pellicciari R. (2002) Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Ther. 303, 1 10.
55. Schwarcz R., Whetsell W. O. Jr. Mangano R. M. (1983) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219, 316 318.
56. Schwarcz R., Foster A. C., French E. D., Whetsell W. O. Jr. Köhler C. (1984) Excitotoxic models for neurodegenerative disorders. Life Sci. 35, 19 32.
57. +-independent transporter of neutral amino acids in astrocytes. J. Neurosci. 9, 2066 2072.
58. Stone T. W. (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 45, 309 379.
59. Stone T. W. Darlington L. G. (2002) Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 1, 609 620.
60. Turski W. A., Gramsbergen J. B., Traitler H. Schwarcz R. (1989) Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine. J. Neurochem. 52, 1629 1636.
61. Wu H.-Q. Schwarcz R. (1996) Seizure activity causes elevation of endogenous extracellular kynurenic acid in the rat brain. Brain Res. Bull. 39, 155 162.